| Filed On | Filing |
|---|---|
| 09 Nov 2026 | SCHEDULE 13D/A |
| 05 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | S-3ASR |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
CLYM116 Phase 1 data in healthy volunteers showed sustained >90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose, supporting every-12-week dosing |
| 28 Oct 2026 | SCHEDULE 13G |
| 27 Oct 2026 | SCHEDULE 13G |
| 26 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Forward Looking Statements This presentation contains “forward-looking statements” including, without limitation, statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding the therapeutic benefi... |
| 23 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026 |
| 30 Sep 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., Director and 6 others
Received 70,000 shares by exercise or conversion ($195K) |
| 17 Sep 2026 |
Form 4: Thomas Stephen Basil, Director
Sold 100,000 shares ($1.37M) |
| 15 Sep 2026 | 144 |
| 03 Sep 2026 |
8-K: Regulation FD Disclosure
R&D Spotlight: CLYM116 Initial Phase 1 Results September 3, 2026 Exhibit 99.2 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 |
8-K: Other Events
On August 13, 2026, Beijing Mabworks Biotech Co., Ltd. announced the dosing of the first patient with immunoglobulin A nephropathy in a Phase 2 clinical trial in China, which is being conducted in collaboration with Climb Bio, Inc. |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 |
| 08 Jul 2026 | SCHEDULE 13G |
| 07 Jul 2026 | SCHEDULE 13D/A |
| 01 Jul 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., Director and 6 others
Granted 70,284 Stock Option (Right to Buy) |
Loading...